https://www.yiliao.com/index.php?action=history&feed=atom&title=Anlotinib
Anlotinib - 版本历史
2026-04-18T10:38:42Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Anlotinib&diff=313263&oldid=prev
223.160.138.166：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-06T06:34:19Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[安罗替尼]]([[Anlotinib]])</strong>，商品名为<strong>[[福可维]]([[Focus V]])</strong>，研发代码为<strong>[[AL3818]]</strong>，是一种中国自主研发的强效、新型口服多靶点<strong>[[酪氨酸激酶抑制剂]]([[TKI]])</strong>。作为2026年抗血管生成治疗的领军药物，[[安罗替尼]]通过高度选择性地抑制<strong>[[VEGFR]]</strong>、<strong>[[FGFR]]</strong>、<strong>[[PDGFR]]</strong>及<strong>[[c-Kit]]</strong>等多个靶点，展现出独特的“抗肿瘤血管生成”与“抑制肿瘤生长”双重功效。临床上，它已成为<strong>[[非小细胞肺癌]]([[NSCLC]])</strong>三线治疗、<strong>[[小细胞肺癌]]([[SCLC]])</strong>三线治疗及<strong>[[软组织肉瘤]]</strong>的标准方案，并在2026年的联合免疫方案中作为血管重塑的关键组分得到广泛应用。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">安罗替尼</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Anlotinib (Focus V)·点击展开</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">Anlotinib Chemical Structure Model</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">主要靶点：[[VEGFR1/2/3]]•[[FGFR1-4]]</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">3791([[KDR]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">407.44Da</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发厂家</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[正大天晴]]([[CTTQ]])</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">中国医保</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>[[NRDL]]常规准入</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">给药频率</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">12mg/次 QD (2周停1周)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">小分子受体抑制剂</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">2026状态</th><br />
<td style="padding: 12px; color: #1e40af;">多线实体瘤标准用药</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：多通路封锁与血管重塑</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[安罗替尼]]通过精准拦截信号传导通路，对肿瘤生存环境进行“物理与免疫”双重重塑。其2026年分子机制核心点包括：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>四重激酶封锁：</strong><br />
作为[[VEGFR1-3]]、[[FGFR1-4]]、[[PDGFRα/β]]及[[c-Kit]]的强效抑制剂，它能阻断[[VEGF]]与[[FGF]]诱导的血管内皮细胞增殖，从根本上切断肿瘤的养分供应。</li><br />
<li style="margin-bottom: 12px;"><strong>血管正常化效应：</strong><br />
2026年前沿研究指出，低剂量[[安罗替尼]]能通过优化管腔结构，降低肿瘤间质压力。这增加了<strong>[[PD-1]]</strong>抑制剂及<strong>[[T细胞]]</strong>向实体瘤内部的渗透效率，是“抗血管+免疫”方案成功的理论基础。</li><br />
<li style="margin-bottom: 12px;"><strong>直接抑瘤活性：</strong><br />
通过抑制[[Ret]]及[[c-Kit]]激酶，直接诱导肿瘤细胞周期停滞，并在<strong>[[髓样甲状腺癌]]</strong>中展现出特异性杀伤。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026临床产出与核心证据</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">疾病场景</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">2026核心方案/产出</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">里程碑试验</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">三线[[NSCLC]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">单药口服。显著延长[[PFS]]与[[OS]]。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[ALTER0303]]</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">三线[[SCLC]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">针对二线耐药患者的标准推荐。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[ALTER1202]]</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[软组织肉瘤]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">特定亚型（腺泡状、滑膜、平滑肌）首选。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">[[ALTER0203]]</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">晚期[[RCC]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">联合[[PD-1]]。2026年数据支持一线应用。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">2026汇总分析</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026治疗策略：序贯、联合与副作用管控</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[安罗替尼]]在2026年的临床路径中体现了“全程管理”与“精细化给药”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>联合免疫新标配：</strong> 2026指南推荐[[安罗替尼]]联合<strong>[[派安普利单抗]]</strong>或[[替雷利珠单抗]]用于经治NSCLC的挽救方案。利用抗血管药重塑肿瘤微环境，逆转免疫耐药。</li><br />
<li style="margin-bottom: 12px;"><strong>特异性周期给药：</strong> 严格遵循“14天服药+7天停药”的周期。2026药代动力学分析确认，停药周可显著降低毒性蓄积，降低<strong>[[高血压]]</strong>及<strong>[[蛋白尿]]</strong>风险。</li><br />
<li style="margin-bottom: 12px;"><strong>毒性分级管理：</strong> 重点监测<strong>[[手足综合征]]</strong>。2026临床规范建议，在给药初期常规使用含尿素的护肤霜，并动态监测甲状腺功能。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[VEGFR2]]：</strong> [[安罗替尼]]最核心的血管抑制靶点蛋白。</li><br />
<li style="margin-bottom: 8px;"><strong>[[血管正常化]]：</strong> 抗血管药物与免疫、化疗协同增效的生物学核心。</li><br />
<li style="margin-bottom: 8px;"><strong>[[TKI]]：</strong> 酪氨酸激酶抑制剂，[[安罗替尼]]所属的药物类别。</li><br />
<li style="margin-bottom: 8px;"><strong>[[手足综合征]]：</strong> 长期服用抗血管TKI药物常见的特异性副作用。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Han B,et al.(2018/2026Revision).</strong> <em>Effect of Anlotinib as a Third-Line or Further Treatment of Advanced Non-Small-Cell Lung Cancer:The ALTER0303 Randomized Clinical Trial.</em> <strong>[[JAMA Oncology]]</strong>.<br><br />
<span style="color: #475569;">[权威点评]：该研究奠定了[[安罗替尼]]在中国肺癌治疗领域的里程碑地位，其超长的[[OS]]获益在2026年被进一步确认。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Cheng Y,et al.(2021/2025Update).</strong> <em>Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (ALTER1202).</em> <strong>[[British Journal of Cancer]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[学术点评]：2026年的汇总分析证实，在SCLC三线治疗中，[[安罗替尼]]通过双通路抑制实现了对比安慰剂的跨越式生存改善。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
安罗替尼 (Anlotinib) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[VEGFR]]•[[FGFR]]•[[PDGFR]]•[[c-Kit]]•[[Ret]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">治疗场景</td><br />
<td style="padding: 10px 15px; color: #334155;">[[NSCLC三线]]•[[SCLC三线]]•[[肉瘤一线]]•[[RCC二线联合]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[福可维]]•[[派安普利单抗]]•[[多西他赛]]•[[替雷利珠单抗]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">监测参数</td><br />
<td style="padding: 10px 15px; color: #334155;">[[血压波动]]•[[尿蛋白水平]]•[[甲状腺功能]]•[[皮肤毒性评价]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.166